Table 1 Baseline characteristics of study cohort by use of low-dose aspirin before and after propensity score matching
Characteristic * | Initial cohort | Propensity score matched cohort | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Aspirin non-user | Low-dose aspirin user | d †| Aspirin non-user | Low-dose aspirin user | d †| ||||||
(N = 244,882) | (N = 16,183) | (N = 15,849) | (N = 15,849) | ||||||||
N | (%) | N | (%) | N | (%) | N | (%) | ||||
Gender | Male | 144,933 | (59.2) | 9,192 | (56.8) | 0.0483 | 8,877 | (56.0) | 8,986 | (56.7) | 0.0139 |
Female | 99,949 | (40.8) | 6,991 | (43.2) | Â | 6,972 | (44.0) | 6,863 | (43.3) | Â | |
Age | 40-49 | 73,569 | (30.0) | 3,806 | (23.5) | 0.3481 | 3,631 | (22.9) | 3,737 | (23.6) | 0.0158 |
50-59 | 76,267 | (31.1) | 5,165 | (31.9) | 0.0356 | 4,690 | (29.6) | 5,067 | (32.0) | 0.0516 | |
60-69 | 57,709 | (23.6) | 4,433 | (27.4) | 0.1971 | 4,489 | (28.3 | 4,342 | (27.4) | 0.0207 | |
70-99 | 37,337 | (15.2) | 2,779 | (17.2) | 0.1385 | 3,039 | (19.2) | 2,703 | (17.1) | 0.0551 | |
Insurance type | Health insurance | 225,785 | (92.2) | 14,896 | (92.0) | 0.0212 | 14,032 | (88.5) | 14,615 | (92.2) | 0.1250 |
Medicaid | 15,399 | (6.3) | 947 | (5.9) | 0.0779 | 1,334 | (8.4) | 920 | (5.8) | 0.1018 | |
Switching | 3,698 | (1.5) | 340 | (2.1) | 0.3086 | 483 | (3.0) | 314 | (2.0) | 0.0681 | |
Type of diabetes | Type 1 only | 10,505 | (4.3) | 910 | (5.6) | 0.0615 | 1,011 | (6.4) | 809 | (5.1) | 0.0548 |
| Â | Type 2 and others | 234,377 | (95.7) | 15,273 | (94.4) | Â | 14,838 | (93.6) | 15,040 | (94.9) | Â |
Antidiabetic medication | OHA | 206,194 | (84.2) | 14,315 | (88.5) | 0.1241 | 13,078 | (82.5) | 14,101 | (89.0) | 0.1854 |
OHA + insulin | 38,688 | (15.8) | 1,868 | (11.5) |  | 2,771 | (17.5) | 1,748 | (11.0) |  | |
Diagnosis of essential hypertension | Yes | 56,688 | (23.1) | 7,912 | (48.9) | 0.5566 | 8,379 | (52.9) | 7,624 | (48.1) | 0.0954 |
Diagnosis of dyslipidemia | Yes | 27,592 | (11.3) | 4,253 | (26.3) | 0.3918 | 4,601 | (29.0) | 4,072 | (25.7) | 0.0749 |
Medication use | Statins | 28,601 | (11.7) | 4,283 | (26.5) | 0.3832 | 4,291 | (27.1) | 4,076 | (25.7) | 0.0308 |
| Â | ACEI | 11,878 | (4.9) | 2,266 | (13.8) | 0.3102 | 2,194 | (13.8) | 2,028 | (12.8) | 0.0308 |
| Â | ARB | 24,597 | (10.0) | 4,321 | (26.7) | 0.4404 | 4,301 | (27.1) | 4,063 | (25.6) | 0.0341 |
| Â | CCB | 47,268 | (19.3) | 6,311 | (39.0) | 0.4439 | 6,552 | (41.3 | 6,099 | (38.5) | 0.0584 |
| Â | Beta blockers | 26,413 | (10.8) | 2,696 | (16.7) | 0.1713 | 3,291 | (20.8) | 2,624 | (16.6) | 0.1082 |
| Â | Thiazide diuretics | 30,824 | (12.6) | 4,481 | (27.7) | 0.3834 | 4,811 | (30.4) | 4,264 | (26.9) | 0.0764 |
| Â | NSAID | 145,733 | (59.5) | 10,155 | (62.8) | 0.0665 | 10,416 | (65.7) | 9,939 | (62.7) | 0.0628 |